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Impaired behavioral activation and effort-related motivational dysfunctions like fatigue
and anergia are debilitating treatment-resistant symptoms of depression. Depressed
people show a bias towards the selection of low effort activities. To determine if the
broadly used antidepressant fluoxetine can improve behavioral activation and reverse
dopamine (DA) depletion-induced anergia, male CD1 mice were evaluated for vigorous
escape behaviors in an aversive context (forced swim test, FST), and also with an
exercise preference choice task [running wheel (RW)-T-maze choice task]. In the FST,
fluoxetine increased active behaviors (swimming, climbing) while reducing passive ones
(immobility). However, fluoxetine was not effective at reducing anergia induced by the
DA-depleting agent tetrabenazine, further decreasing vigorous climbing and increasing
immobility. In the T-maze, fluoxetine alone produced the same pattern of effects as
tetrabenazine. Moreover, fluoxetine did not reverse tetrabenazine-induced suppression
of RW time but it reduced sucrose intake duration. This pattern of effects produced
by fluoxetine in DA-depleted mice was dissimilar from devaluing food reinforcement
by pre-feeding or making the food bitter since in both cases sucrose intake time
was reduced but animals compensated by increasing time in the RW. Thus, fluoxetine
improved escape in an aversive context but decreased relative preference for active
reinforcement. Moreover, fluoxetine did not reverse the anergic effects of DA depletion.
These results have implications for the use of fluoxetine for treating motivational
symptoms such as anergia in depressed patients.
Keywords: dopamine, fluoxetine, serotonin, motivation, effort, vigor, depression
INTRODUCTION
Motivational symptoms such as psychomotor retardation, anergia, lack of energy, lassitude,
fatigue, and reduced exertion of effort are common and critical in major depressive disorder
(Stahl, 2002; Demyttenaere et al., 2005; Salamone et al., 2007; Treadway and Zald, 2011).
These highly debilitating symptoms in depression are strongly correlated with problems with social
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function and employment (Tylee, 1999; Stahl, 2002, 2017;
Hodgetts et al., 2017). They are also highly resistant to treatment
and often remain as residual symptoms after remission (Stahl,
2002; Nutt et al., 2007; Fava et al., 2014). Many common
antidepressants including serotonin (5-HT) transporter (SERT)
inhibitors such as fluoxetine and citalopram are useful for
treating mood symptoms in depression (Rosenblau et al., 2012;
Rizvi et al., 2013; Hieronymus et al., 2016), but they are relatively
ineffective for treating motivational dysfunctions, and, in fact,
it has been suggested that SERT inhibitors may exacerbate or
induce these symptoms in some patients (Nutt et al., 2007;
Targum and Fava, 2011; Padala et al., 2012; Stenman and
Lilja, 2013; Fava et al., 2014; Rothschild et al., 2014). However,
systematic studies are still lacking.
Because of the clinical significance of motivational
dysfunctions, it is critical to develop animal models that
allow researchers to study a broad range of impairments, and
also to assess the ability of different drugs to reverse them.
Thus, some studies have focused upon different tasks involving
effort-based decision-making that offer rodents the possibility
of choosing between high-effort instrumental actions leading
to more valued reinforcers or to choose the low-effort options
leading to less valued reinforcers. Conditions associated with
depression, including stress (Shafiei et al., 2012; Bryce and
Floresco, 2016, 2019) and pro-inflammatory cytokines (Nunes
et al., 2014; Goldsmith et al., 2016; Yohn et al., 2016a), as well as
dopamine (DA) receptor antagonism (Pardo et al., 2012, 2015;
Yohn et al., 2015a; Correa et al., 2016; Yang et al., 2020) or DA
depletion (Nunes et al., 2013; Randall et al., 2014; Yohn et al.,
2015b; López-Cruz et al., 2018; Rotolo et al., 2019; Carratalá-Ros
et al., 2020) can affect effort-related decision-making and bias
animals towards the low effort options. These results obtained
from animal studies are consistent with clinical data showing
a reduced selection of high effort alternatives in depressed
people tested on tasks of effort-based choice (Treadway et al.,
2012; Chong et al., 2016). Administration of the vesicular
monoamine transporter (VMAT-2) inhibitor tetrabenazine
(TBZ), which blocks the monoamine storage and leads to a
striatal DA depletion at low doses in primates (Pettibone et al.,
1984), rats (Nunes et al., 2013; Podurgiel et al., 2015, 2016; Yohn
et al., 2015b), and mice (López-Cruz et al., 2018; Carratalá-Ros
et al., 2020) has been used to induce effort-related motivational
impairments in rodents (Nunes et al., 2014; Yohn et al., 2015b,
2016b; Correa et al., 2018; López-Cruz et al., 2018; Rotolo
et al., 2019; Carratalá-Ros et al., 2020). This drug is used in
the treatment of Huntington’s disease and has been reported
to produce depressive symptoms including fatigue in people
(Frank, 2009; Guay, 2010). Recently, we have also demonstrated
that TBZ induces depressive symptoms in the forced swim test
(FST); mice show less vigorous scaping behaviors and increase
immobility (Carratalá-Ros et al., 2020).
Willingness to do effort can also be studied in a recreational
context in which there is no stress from which to escape, and
no work required to obtain a meal. Thus, voluntary vigorous
wheel running was used in a recently developed T-maze choice
task as the high effort/highly preferred option (Correa et al.,
2016; López-Cruz et al., 2018; Carratalá-Ros et al., 2020).
This paradigm assesses the impact of drugs, homeostatic or
environmental manipulations on behavioral activation, and
effort-related choice. This task allows the animal to freely
choose between running on a running wheel (RW), consuming
sucrose pellets, or sniffing a neutral non-social odor. It has
been demonstrated that TBZ produced a dose-dependent shift in
response selection, reducing preference for the energy-requiring
reinforcer (wheel running), but concurrently increasing time
with the second preferred reinforcer (palatable food) that
required little effort to obtain (López-Cruz et al., 2018; Carratalá-
Ros et al., 2020). Thus, animals do not show anhedonia
towards the food but show an anergic behavioral pattern.
This is also a model of voluntary physical activity. It has
been observed that a lack of activity can contribute to the
development of depression (Lambert, 2006), and in depressed
people, symptoms such as loss of interest, motivation and energy,
and generalized fatigue problems interfere with participation
in exercise (Knapen et al., 2015), especially because the
choice to engage in voluntary physical activity is always
undertaken in relation to the possible selection of other more
sedentary alternatives.
The ability of antidepressants that are monoamine uptake
inhibitors to reverse the effects of TBZ on effort-based choice
in rodents differs depending upon their specific mechanism
of action. For example, SERT inhibitors such as fluoxetine or
s-citalopram failed to reverse the low-effort bias induced by TBZ
in rats tested in operant paradigms in which animals had to
work (lever press) to get access to more palatable food or could
choose to approach and consume a less preferred but freely
available chow (Yohn et al., 2016b,c,e). Moreover, fluoxetine
either acutely or chronically administered had the same impact
on effort-based choice (Yohn et al., 2016b,c,e). These behavioral
effects of fluoxetine were paralleled by a reduction in nucleus
accumbens (Nacb) core DA levels (Yohn et al., 2016b,c,e).
However, DA transport (DAT) inhibitors reverse TBZ effects
on effort-based-choice and increased DA in Nacb (Nunes
et al., 2013; Randall et al., 2014; Yohn et al., 2016b,c,d).
On the contrary, in the FST fluoxetine effectively enhances
active behaviors and reduces passive ones (Petit-Demouliere
et al., 2005; Jang et al., 2009), the opposite pattern to TBZ
(Carratalá-Ros et al., 2020).
Since the effects of fluoxetine on activational aspects of
motivation can be seen after acute administration, the present
study explored the effect of fluoxetine administered acutely,
alone or in combination with the DA depleting agent TBZ,
in a non-stressful context (the 3-choice RW T-maze task) that
evaluates relative preference for active reinforcers vs. more
sedentary options, and compared those results with actions in
the FST, which involves a stressful test setting and measures
vigorous scaping vs. passive responses. We also evaluated these
drugs and their combination on measures of anxiety (dark
and light box, DL box and the elevated plus maze, EPM) as
a potential explanation for their effects in those motivational
paradigms. We also compared the effects of fluoxetine with the
effect of behavioral manipulations that change the emotional
or homeostatic value of food on the performance of the RW
T-maze task.
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The proposed work is not presenting a global model
of depression per se, or providing a general screening of
antidepressant drugs, but rather focused on a specific behavioral
component (active exertion of physical effort) that is particularly
important for the motivational symptoms of depression, and
potentially other disorders as well.
MATERIALS AND METHODS
Animals
CD1 adult male mice (N = 106) purchased from Janvier, France
S.A. were 8–14 weeks old (40–50 g) at the beginning of the
study. Mice were housed in groups of three or four per cage,
with standard laboratory rodent chow and tap water available
ad libitum. The colony was kept at a temperature of 22 ± 2◦C
with lights on from 08:00 h to 20:00 h. All animals were under
a protocol approved by the Institutional Animal Care and Use
Committee of Universitat Jaume I. All experimental procedures
complied with directive 2010/63/EU of the European Parliament
and of the Council, and with the ‘‘Guidelines for the Care and
Use of Mammals in Neuroscience and Behavioral Research,’’
National Research Council 2003, USA. All efforts were made
to minimize animal suffering and to reduce the number of
animals used.
Pharmacological Agents
Fluoxetine (CIMYT Quimica SL, Spain) was dissolved in 0.9%
saline and administered 30 min before testing. The range of
doses of fluoxetine was based on studies involving classical
mice antidepressant screening tests (Lucki et al., 2001) and
effort-related behavioral tests (Yohn et al., 2016b,c). In order
to conduct the reversal behavioral experiments, the VMAT-2
blocker tetrabenazine (TBZ; CIMYT Quimica SL, Spain) was
used. TBZ was dissolved in a vehicle solution of 0.9% saline
(80%) plus dimethylsulfoxide (DMSO 20%, final pH 5.5) and
administered 120 min before testing. Time elapsed after injection
and the dose of 8.0 mg/kg TBZ were selected based on previous
behavioral work (Correa et al., 2018; López-Cruz et al., 2018;
Carratalá-Ros et al., 2020) and neurochemical studies (López-
Cruz et al., 2018) demonstrating that in mice this is an optimal
dose and time lead to deplete DA. DMSO (20% v/v) and
saline were used as the control group. All the substances were
administered intraperitoneally (IP).
Testing Procedures
All behavioral procedures started 2 h after the light period
started. The behavioral test room was illuminated with a soft
light, and external noise was attenuated.
Forced Swim Test (FST)
This paradigm is considered to be a model of behavioral despair
and is used as a test for assessing depressive-like states and
for evaluating drugs with potential as antidepressants (Porsolt
et al., 1977). Immobility was defined as the animal remaining
motionless, making only minor movements to balance the body
and keep the head above the water. Mild swimming was recorded
when animals carried out horizontal movements with their
forepaws, leading to the displacement of the body throughout
the swim chamber (Armario et al., 1988). In addition, we
also assessed escape-related mobility such as climbing (Armario
et al., 1988). Climbing is defined as any energetic and vertical
movement of all four limbs against the wall of the tank.
Naïve mice were placed in a transparent cylindrical glass tank
(26 cm high and 18 cm diameter) filled with water (14 cm)
and maintained at a temperature of 25◦C. Water was changed
between animals. During the 6-min test, mice were videotaped
from the side, and climbing, immobility, and swimming were
later measured by an observer unaware of the experimental
condition. After the test, mice were dried with a soft towel, put
back in a box with absorbing paper under a warming light, and
were monitored for 10 min.
Dark and Light Box (DL)
The DL test is based on the conflict between the tendency
to explore a novel environment and the avoidance of a
brightly lit open area (Blumstein and Crawley, 1983). The DL
apparatus consisted of a polypropylene chamber divided into two
compartments by a partition containing a small opening (5 cm
H × 5 cm W). The light compartment (25 cm W × 25 cm
H × 25 cm L) was open, painted in white, and illuminated
(335 lx), while the dark compartment (25 cm W × 25 cm
H× 18 cm L) was painted in black and had a removable ceiling to
close it (Kulesskaya and Voikar, 2014). To start the test session,
mice were individually placed in the dark chamber facing one
corner. Test sessions were videotaped, and the total number of
crosses and the total time spent in the lit chamber were recorded
for 5 min (López-Cruz et al., 2014; Carratalá-Ros et al., 2020).
Elevated Plus Maze (EPM)
The EPM consists of two open and two enclosed arms (65 cm
L × 5 cm W) arranged in a plus configuration and intersecting
in a central platform. It is made of black polypropylene and is
elevated 50 cm above the floor. The open arms have a 1 cm
border around their perimeter and the closed arms have a 20 cm
translucent wall. This anxiety paradigm measures the avoidance
that rodents show to high open spaces. Under normal conditions,
mice spend more time in and make more entries into the closed
arms of the maze (Lister, 1987). Animals were placed in the
central platform with their head pointing at one enclosed arm,
and they were assessed for 5 min. Sessions were videotaped and a
trained observer registered total time spent in the open arms, the
ratio of entries into the open arms compared to total arm entries,
and total entries in the four arms as an index of locomotion. An
entry into an arm was recorded when the animal crossed with
all four legs the line that connected that arm with the central
platform (López-Cruz et al., 2014).
T-Maze RW-Sucrose-Odor Choice Task
The 3-choice-T-maze apparatus consisted of a central area that
led to three arms (López-Cruz et al., 2018). In one of them,
sucrose pellets (TestDietTM, 50% sucrose, 45 mg each) were
available, in another arm there was an RW, and in the third arm,
there was a hole with a cotton ball soaked with a fruity odor.
Training as well as test sessions, lasted 15 min. Mice were trained
in one session per day, 5 days a week. Training phase 1: to avoid
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neophobia to the sweet-tasting pellets, animals were enclosed in
that arm with the food during five initial sessions. Training phase
2: during two more weeks animals were exposed to the T-maze
with free access to the three stimuli, each one in a different arm.
Test phase: This phase lasted between two or five more weeks
depending on the experiment. For each week, there were four
training sessions plus a testing session in which animals received
drug injections or were exposed to the food manipulations. The
day before the food manipulation was considered as the baseline
(BL). Entries into the arms of the T-maze were simultaneously
recorded. All these measures were used based on previous studies
(Correa et al., 2016; López-Cruz et al., 2018; Carratalá-Ros et al.,
2020). Time interacting with the stimuli was selected as the
main dependent measure because it allowed for the evaluation of
interactions with the three different stimuli with the same units
(i.e., time). Time allocation is a useful measure of preference,
relative reinforcement value, and response choice (Baum and
Rachlin, 1969).
Statistical Analyses
All of the experiments were single factor designs, and thus all
experiments were analyzed with either simple between groups
analysis of variance (ANOVA), repeated measures ANOVA,
or Student’s t-test. Normally distributed and homogenous data
(according to Kolmogorov–Smirnov test) for the FST, DL,
and EPM, employed between groups design and data were
analyzed by one-way ANOVA. Normally distributed data in
the T-maze experiment followed a within groups design. Thus,
when more than two experimental conditions were used, such
as in the fluoxetine or the TBZ plus fluoxetine experiments,
data were analyzed by repeated measures ANOVA. When
the overall ANOVA was significant, non-orthogonal planned
comparisons using the overall error term were used to compare
each treatment with the vehicle control group (Keppel, 1991). For
these comparisons, α level was kept at 0.05 because the number
of comparisons was restricted to the number of treatments
minus one. The effects of changing the taste of the pellets
and pre-feeding animals were evaluated by Student’s t-test for
dependent samples. All data were expressed as mean ± SEM,




Effect of fluoxetine in the FST. Different groups of animals
(N = 31) received one dose of fluoxetine (vehicle, 10.0, 15.0, or
20.0 mg/kg) and 30 min after the injection were placed in the
FST for 6 min. Mice were exposed only once to the FST since
behavioral habituation develops in one session.
The one-way ANOVA showed a significant effect on
immobility time (F(3,27) = 5.0, p < 0.01), time swimming
(F(3,27) = 3.41, p < 0.05), and time climbing (F(3,27) = 5.68,
p < 0.01). Planned comparisons revealed that the groups that
received 10.0 and 20.0 mg/kg displayed significantly less time to
be immobile (p< 0.05, p< 0.01 respectively) in comparison with
the vehicle group. The two highest doses of fluoxetine (15.0 and
20.0 mg/kg) produced an increase in time spent swimming
(p < 0.01 and p < 0.05 respectively), and only 20.0 mg/kg of
fluoxetine increased time climbing in the FST (p < 0.01) in
comparison with the vehicle group (Figure 1A).
Experiment 2
Effect of TBZ and fluoxetine combination in the FST. Three
different groups of naïve mice (N = 38) received a combination
of TBZ (8.0 mg/kg, a dose that was shown to be effective in the
FST; Carratalá-Ros et al., 2020) plus vehicle or the highest dose
of fluoxetine (20.0 mg/kg) or the combination of both vehicles.
Fluoxetine was given 90min after TBZ and 30min before animals
were placed in the FST.
The one-way ANOVA for time spent swimming
(F(2,35) = 0.34; p = 0.70) was not significant. However,
the ANOVAs for immobility and climbing were significant
(F(2,35) = 3.76, p < 0.05; F(2,35) = 9.10, p < 0.01 respectively).
Planned comparisons revealed that the group that received TBZ
8.0 mg/kg plus vehicle, and also the group that received TBZ
8.0 + fluoxetine 20.0 mg/kg displayed significantly less climbing
than the vehicle group (p < 0.01). Finally, TBZ+ fluoxetine at
20.0 mg/kg increased the time of immobility compared with the
vehicle group (p < 0.01; Figure 1B).
Experiment 3
Effect of fluoxetine in the DL and EPM paradigms. Independent
groups of mice (N = 35) received one dose of fluoxetine (vehicle,
10.0, 15.0, or 20.0 mg/kg) and 30 min after injection were
first placed in the DL box for 5 min. Immediately after this
test, they were placed in the EPM for five more minutes. Mice
were exposed only once to both paradigms since behavioral
habituation develops in one session.
The one-way ANOVA showed a significant effect on time
spent in the illuminated arena (F(3,31) = 5.11, p < 0.01) of the DL
box. Moreover, the one-way ANOVA also revealed a significant
effect on the total number of entries into both compartments
of the DL box (F(3,31) = 2.99, p < 0.05). Planned comparisons
indicated that mice treated with fluoxetine at 15.0 and at
20.0mg/kg spent less time in the lit chamber (p< 0.01) compared
to the vehicle group. Moreover, the highest dose of fluoxetine
produced a decrease in the total number of entries into both
compartments (p < 0.01) in comparison with the vehicle group
(Figures 2A,B). The one-way ANOVA for the effect of fluoxetine
in the EPM showed a significant effect on the ratio of entries into
the open arms (F(3,31) = 7.49, p < 0.01). Planned comparisons
showed that all doses of fluoxetine reduced the ratio of entries
compared to vehicle (p < 0.01; Figure 2D). However, the
one-way ANOVA did not show a significant effect on time spent
in the open arms (F(3,31) = 1.91, p = 0.14) or the total number
of entries into all arms of the EPM (F(3,31) = 0.25, p = 0.85;
Figures 2C,E).
Experiment 4
Effect of TBZ and fluoxetine combination in the DL and EPM
paradigms. Three different groups of naïve mice (N = 32)
received a combination of TBZ (8.0 mg/kg) plus vehicle or
the highest dose of fluoxetine (20.0 mg/kg) or the combination
of both vehicles. Fluoxetine was given 90 min after TBZ and
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FIGURE 1 | Effect of fluoxetine (Vehicle, 10, 15 or 20 mg/kg) (A) and tetrabenazine (TBZ) plus fluoxetine combination (Veh + Veh, TBZ + Veh, or TBZ + Fluoxetine
20 mg/kg (B) on the duration of immobility, swimming, and climbing behavior in the forced swim test (FST) assessed for 6 min. Groups were analyzed using one-way
analysis of variance (ANOVA) for independent samples in each dependent variable. Bars represent mean ± SEM of accumulated seconds. ∗p < 0.05,
∗∗p < 0.01 significantly different from the control group.
FIGURE 2 | Effect of fluoxetine (Vehicle, 10, 15 or 20 mg/kg) on time spent in the lit chamber (A) and the total of entries between the two compartments (B) of the
DL box, and on time spent in the open arms (C), ratio to the open arms (D), and the total of entries to the four arms (E) of the EPM during 5 min each test. Groups
were analyzed using one-way ANOVA for independent samples in each dependent variable. Bars represent mean ± SEM of accumulated seconds.
∗∗p < 0.01 significantly different from the vehicle group. Abbreviations: DL box, dark and light box; EPM, elevated plus maze.
30 min before animals were placed in the DL box for 5 min, and
immediately after this test, they were placed in the EPM for five
more minutes.
The one-way ANOVAs did not show any significant effect
of the treatment on anxiety parameters such as time spent in
the lit chamber of the DL box (F(2,27) = 1.23, p = 0.30), time
spent in the open arms (F(2,27) = 2.27, p = 0.80) or ratio of
entries (F(2,27) = 1.69, p = 0.20) evaluated in the EPM paradigm
(Figure 3). However, different one-way ANOVAs did show
significant effects on locomotion seen in the total of entries
between the two compartments of the DL box (F(2 27) = 16.93,
p < 0.01), and the total of entries into all arms of the EPM
(F(2,27) = 6.64, p < 0.01). Planned comparisons revealed that
the groups treated with 8.0 mg/kg of TBZ plus vehicle and
the combination of TBZ plus fluoxetine both decreased the
total number of entries in comparison with the vehicle group
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(p < 0.01) in the DL box (Figure 3B). The same effect was
observed in the EPM: the groups treated with TBZ plus vehicle,
and TBZ plus fluoxetine were different from the vehicle treated
group (p < 0.01; Figure 3E).
Experiment 5
Effect of fluoxetine on preference for active reinforcers in
the 3-choice-T-maze task. After reaching a stable BL level of
performance in the T-maze, animals (N = 10) received fluoxetine
(vehicle, 10.0, 15.0, and 20.0 mg/kg) and, after 30 min, were
placed in the T-maze for 15 min. Since BL behavior does not
change, animals received one dose of the drug every week
in a randomly varied order. The T-maze paradigm requires a
BL performance of 2 weeks before drug tests start, and that
performance was maintained across weeks, thus allowing a
repeated measures design.We have observed that fluoxetine does
not produce sensitization or tolerance when administered once
per week.
Repeated measures ANOVA showed that fluoxetine did
not produce any significant effect on time spent sniffing
the neutral odor (F(3,27) = 0.90, p = 0.45). However,
fluoxetine produced a significant effect on time spent eating
(F(3,27) = 6.26, p < 0.01), and time spent running in the RW
(F(3,27) = 15.13, p < 0.01). Planned comparisons revealed
that fluoxetine 20.0 mg/kg treated-mice spent significantly
more time consuming sucrose pellets (p < 0.01), and
less time running in the RW (p < 0.01) compared to the
vehicle group (Figures 4A–C). Finally, repeated measures
ANOVAs indicated that fluoxetine did not produce significant
effects on the number of entries into the food compartment
(F(3,27) = 0.97, p = 0.42), and into the neutral odor compartment
(F(3,27) = 1.98, p = 0.14). However, the SERT inhibitor
did significantly reduce the total number of entries into
the RW compartment (F(3,27) = 5.43, p < 0.01). Planned
comparisons revealed that all doses of fluoxetine produced
a decrease in the total of entries to the RW compartment in
comparison with the vehicle group (p < 0.01; data shown in
Figure 4D).
Experiment 6
Effect of TBZ and fluoxetine combination on preference for
active reinforcers in the 3-choice-T-maze task. The same
statistical design was used. A new group of mice (N = 9) received
TBZ (veh, 8.0 mg/kg) and, 90 min later, a dose of fluoxetine
(veh, 10.0, 15.0, 20.0 mg/kg), 30 min later they were placed in the
T-maze during 15 min. Animals received one drug combination
(veh-veh, TBZ-veh, TBZ-10, TBZ-15 and TBZ20 mg/kg) every
week during 5 weeks in a random varied order.
Repeated measures ANOVA showed a significant effect of
treatment on time spent eating sucrose pellets (F(4,32) = 3.33,
p < 0.05) and time spent running in the RW (F(4,32) = 3.86,
p < 0.01), but no significant effect on time sniffing the neutral
odor (F(4,32) = 0.77, p = 0.54). Planned comparisons showed that
mice treated with TBZ 8.0 mg/kg plus vehicle spent less time
running (p < 0.05) than the vehicle-vehicle control condition.
Also, fluoxetine suppressed time running in the RW in TBZ-
treated mice at doses of 15.0 and 20.0 mg/kg in comparison with
the vehicle-vehicle condition (p< 0.05 and p< 0.01 respectively).
Planned comparisons for time consuming sucrose revealed that
mice treated with TBZ plus vehicle increased time consuming
sucrose pellets (p < 0.01) in comparison with the vehicle-
vehicle group, but all doses of fluoxetine in combination with
FIGURE 3 | Effect of TBZ plus fluoxetine combination (Veh + Veh, TBZ + Veh, or TBZ + Fluoxetine 20 mg/kg) on time spent in the lit chamber (A) and the total of
entries between the two compartments (B) of the DL box, and on time spent in the open arms (C), ratio to the open arms (D), and the total of entries to the four
arms (E) of the EPM during 5 min each test. Each dependent variable was analyzed by one-way ANOVA for independent samples. Bars represent mean ± SEM of
accumulated seconds. ∗∗p < 0.01 significantly different from vehicle-vehicle group.
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FIGURE 4 | Effect of fluoxetine (Vehicle, 10, 15 and 20 mg/kg) on time eating (A), time running (B), time sniffing (C), entries into compartments (D), and in the
T-maze task assessed during 15 min. Data for each variable were analyzed by repeated measures ANOVA. Bars represent mean ± SEM of accumulated seconds or
number of entries. ∗∗p < 0.01 significantly different from vehicle.
TBZ suppressed time consuming sucrose pellets (for TBZ+
10.0 and TBZ+15.0 mg/kg p < 0.05 and for TBZ+20 mg/kg
p < 0.01) in comparison with the TBZ plus vehicle condition
(Figures 5A–C).
Finally, repeated measures ANOVAs showed a significant
effect of treatment on the number of entries to the RW
compartment (F(4,32) = 2.89, p < 0.05), entries into the
food compartment (F(4,32) = 5.46, p < 0.01), and total
entries into the odor compartment (F(4,32) = 3.46, p < 0.01).
Planned comparisons showed that TBZ+ fluoxetine at 15.0 and
20.0 mg/kg produced a decrease in entries into the RW
compartment (p < 0.05), and into the food compartment
(p < 0.05 and p < 0.01 respectively) compared with their
respective vehicle condition. Only the highest dose of fluoxetine
(20.0 mg/kg) in combination with TBZ decreased entries to the
odor compartment (p < 0.01) in comparison with the vehicle
condition (Figure 5D).
Experiment 7
Manipulations that devalue sucrose reinforcement: change in
taste with bitter pellets. Animals (N = 8) were trained as described
before, and after reaching stable levels of interaction with the
three different reinforcers, a drop of quinine (1.0 g/L) was added
to the sweet pellets in order to make them bitter. BL behavior was
assessed the day before the bitter pellets were substituted for the
regular ones.
A series of Student’s t-tests for dependent samples for each
variable showed a significant effect of bitter pellets (t(5) = 4.56,
p< 0.01) on time running and on time spent eating (t(5) =−2.53,
p < 0.01) compared with their respective BL. However, there
was no significant effect of bitter food on time sniffing the
neutral odor (t = 2.0, p = 0.10; Figures 6A–C). Finally, t-
tests for dependent samples failed to demonstrate significant
differences between both conditions on total entries to the food
compartment (t(5) = −0.09, p = 0.92), total entries to the RW
compartment (t(5) =−2.23, p = 0.07), and total entries to the odor
compartment (t(5) = −0.58, p = 0.58; Figure 6D).
Experiment 8
Manipulations that devalue sucrose reinforcement: change in
appetite by pre-feeding. After training, BL performance of mice
(N = 12) was recorded. Overnight animals were pre-exposed
to sweet pellets ad libitum, and the following day, the test
session started.
The Student’s t-test for dependent samples showed a
significant increase in time running in the RW (t(11) = −3.87,
p < 0.01), and a decrease in time eating sucrose pellets
(t(11) = 2.95, p < 0.01) in the pre-feed condition compared
with the control condition (Figures 7A,B). However, there
was no significant effect of pre-feeding on time spent sniffing
the neutral odor (t(11) = −0.82, p = 0.42; Figure 7C).
The t-tests revealed no statistical differences in number of
entries into the food compartment (t(11) = 1.51, p = 0.15),
entries into the RW compartment (t = −1.02, p = 0.32) and
entries into the odor compartment (t(11) = −1.42, p = 0.18;
Figure 7D).
Frontiers in Behavioral Neuroscience | www.frontiersin.org 7 July 2021 | Volume 15 | Article 700182
Carratalá-Ros et al. Fluoxetine and Anergia
FIGURE 5 | Effect of TBZ (Vehicle or 8 mg/kg) plus fluoxetine (Vehicle, 10, 15, and 20 mg/kg) combination on time eating (A), time running (B), time sniffing (C),
entries into compartments (D), and in the T-maze task assessed during 15 min. Repeated measures ANOVA was used to analyze each variable. Bars represent
mean ± SEM of accumulated seconds or number of entries. ∗p < 0.05, ∗∗p < 0.01 significantly different from Veh + Veh. #p < 0.05, ##p < 0.01 significantly different
from TBZ + Veh.
FIGURE 6 | Effect of bittering the sucrose pellets on time eating (A), time running (B), time sniffing (C), entries into compartments (D), and in the T-maze task
assessed during 15 min. Data were analyzed with the Student’s t-test for dependent samples. Bars represent mean ± SEM of accumulated seconds or number of
entries. ∗∗p < 0.01 significantly different from baseline (BL) condition.
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FIGURE 7 | Effect of pre-feeding on time eating (A), time running (B), time sniffing (C), entries into compartments (D), and in the T-maze task assessed during
15 min. Data were analyzed using the Student’s t-test for dependent samples. Bars represent mean ± SEM of accumulated seconds or number of entries.
∗∗p < 0.01 significantly different from BL condition.
Experiment 9
Effect of pharmacological and food manipulations on amount
of sucrose consumption, or locomotion in the T-maze. Data
on pellets consumed (in milligrams) or crosses between
compartments in the T-maze from experiments 5, 6, 7, and
8 were analyzed comparing each experimental condition with its
respective control condition (vehicle or BL).
The Student’s t-test for dependent samples showed significant
differences in the number of pellets consumed when animals
received fluoxetine 20.0 mg/kg in comparison with their vehicle
condition (t(9) = −3.13, p < 0.01). However, the t-test
comparison of vehicle-vehicle with TBZ-vehicle did not show a
significant effect (t(7) = −0.67, p = 0.52), and a separate t-test
between vehicle-vehicle and TBZ-fluoxetine 20.0 mg/kg was not
significant either (t(7) = 0.88, p = 0.40). There were significant
differences in the number of pellets consumed when animals
were pre-fed (t(11) = 2.62, p < 0.05), or had access to bitter
food (t(5) = 3.43, p < 0.05) compared to their respective controls
(Table 1). The Student’s t-test for dependent samples showed
significant differences in spontaneous locomotion in the T-maze
when mice received fluoxetine 20.0 mg/kg in comparison with
the vehicle condition (t(9) = 2.53, p < 0.05). However, the t-test
comparison of vehicle-vehicle with TBZ-vehicle did not show
a significant effect (t(7) = −3.11, p = 0.35) although a separate
t-test between vehicle-vehicle and TBZ-fluoxetine 20.0 mg/kg
was significant (t(7) = 2.83, p < 0.05). Finally, there were no
significant differences in spontaneous locomotion in the T-maze
when animals were pre-feed (t(11) = −0.43, p = 0.67) or had
access to bitter pellets (t(5) = −1.01, p = 0.35; data are shown
in Table 2).
TABLE 1 | Effect of tetrabenazine (TBZ) and fluoxetine alone or in combination,
and food manipulations on pellets intake.
Pellet intake (mg in 15 min)
Control condition Experimental condition
Exp. 5. Fluoxetine 112.5 ± 40.4 306.0 ± 74.9∗∗
Exp. 6. TBZ 129.4 ± 54.1 196.9 ± 64.7
Exp. 6. TBZ+ Fluoxetine 129.4 ± 54.1 61.9 ± 35.0
Exp. 7. Bitter food 345.0 ± 104.4 41.3 ± 28.7∗
Exp. 8. Pre-feeding 240.0 ± 50.7 60.0 ± 15.0∗
Mean (± SEM) of milligrams consumed during the T-maze test. Data were analyzed using
a series of Student’s t-test for dependent samples. ∗p < 0.05, ∗∗p < 0.01 significantly
different from its respective control condition.
TABLE 2 | Effect of tetrabenazine (TBZ) and fluoxetine alone or in combination,
and food manipulations on general locomotion.
Locomotion in the T-maze (crosses in 15 min)
Control condition Experimental condition
Exp. 5. Fluoxetine 41.5 ± 8.8 24.5 ± 4∗
Exp. 6. TBZ 19.4 ± 2.4 22.5 ± 2.3
Exp. 6. TBZ+ Fluoxetine 19.4 ± 2.4 9.1 ± 2.1∗
Exp. 7. Bitter food 27.6 ± 2.8 33.0 ± 1.5
Exp. 8. Pre-feeding 49.0 ± 10.0 50.8 ± 9.7
Mean (± SEM) of total entries to the three compartments of the T-maze test. Data
were analyzed using Student’s t-test for dependent samples in each experiment.
∗p < 0.05 significantly different from its respective control condition.
DISCUSSION
The present experiments evaluated the ability of the 5-HT uptake
inhibitor fluoxetine to produce antidepressant effects on the
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classical rodent paradigm, the FST, and also its potential to
reverse the depression-like effects of the DA depleting agent TBZ
in this paradigm (Carratalá-Ros et al., 2020). We confirmed that
administration of a range of doses of fluoxetine significantly
increased the time mice spent climbing and swimming,
consequently reducing the time animals spent immobile in the
FST (Figure 1). Previous studies have shown the same pattern;
fluoxetine increases active behaviors (swimming and climbing)
and decreases passive ones (immobility) in different strains of
mice after acute or chronic administration of this SERT blocker
(Lucki et al., 2001; Dulawa et al., 2004; Sanmukhani et al., 2011;
Costa et al., 2013). However, when we evaluated the ability of the
highest dose of fluoxetine (20.0 mg/kg) to reverse the anergic
effects produced by the DA depleting agent TBZ in the FST
(Carratalá-Ros et al., 2020), we observed that fluoxetine failed
to reverse the effects of TBZ. Thus, animals that received the
combination of TBZ and fluoxetine significantly increased time
spent immobile and decreased time spent climbing, suggesting
that fluoxetine is not able to alleviate motivational deficits in
swimming and climbing induced by DA depletion. TBZ was
used in this study as a tool for altering behavioral activation and
effort-related choice since this drug has been reported to induce
depressive symptoms including fatigue in people (Frank, 2009;
Chen et al., 2012) and behavioral impairments in traditional
rodent depressionmodels (Wang et al., 2010; Carratalá-Ros et al.,
2020), and effort-based choice tasks (Nunes et al., 2013; Yohn
et al., 2016b; López-Cruz et al., 2018; Rotolo et al., 2019). These
actions are likely to be produced by DA depletion since depletion
of 5-HT had no effect on effort-related decision making (Denk
et al., 2005). More importantly, it has been shown that a low
dose of TBZ in rats reduced striatal DA by about 75%, while this
same dose reduced 5-HT and NE by about 15–30% (Pettibone
et al., 1984). Moreover, TBZ is 10 times more potent at reducing
striatal tissue DA than at reducing 5-HT. Similar results were
shown by Tanra et al. (1995), who reported that a low dose of
TBZ administered to rats produced a 57% reduction in striatal
DA, whereas, with 5-HT, there were no significant reductions
in frontal cortex, striatum or hippocampus, and only a 20%
reduction in the hypothalamus. Fuenmayor and Vogt (1979)
showed that a dose of TBZ that reduced striatal DA by 87% only
reduced by 51%.
The antidepressant-like effect of fluoxetine alone in the
FST cannot be explained by anxiolytic actions since the same
doses of fluoxetine that had an antidepressant effect in the
FST, also increased anxiety-related parameters evaluated in
the DL box and EPM paradigms. Thus, mice that received the
two highest doses of fluoxetine (15.0 and 20.0 mg/kg) spent
significantly less time in the lit chamber of the DL box and
reduced the ratio of entries in the open arms of the EPM
paradigm (Figure 2). Some animal studies have shown that
acute administration of doses of fluoxetine like the ones used
in the present study (20.0 mg/kg) produce anxiogenic effects
in rats (Greenwood et al., 2008), and mice (Kurt et al., 2000;
Belzung et al., 2001). It also has been shown that null-SERT
mutant mice usually display anxious behaviors (Holmes et al.,
2002). Moreover, using a chemogenetic approach, although
both acute- and chronic activation of dorsal raphe nucleus
serotonergic neurons induce antidepressant-like responses in
the FST, only acute activation induces anxiogenic-like behaviors
in rats (Urban et al., 2016). It is possible that fluoxetine
induced an acute anxiety response that energizes escape-oriented
behaviors in a context that is already stressful. On the other
hand, in the present and previous experiments, TBZ showed
no anxiogenic effects at a broad range of doses (Correa
et al., 2018; Carratalá-Ros et al., 2020). Interestingly, unlike
fluoxetine alone, the combination of fluoxetine plus TBZ did
not produce anxiety-related effects in any of the paradigms
(Figure 3).
The FST provides some information about behaviors related
to the maintenance of vigorous and persistent active responding
(Gil and Armario, 1998; Slattery and Cryan, 2012) in order
to escape a stressful and unknown situation. In addition, we
decided to evaluate the effects of fluoxetine in a non-stressful
habitual context; the 3-choice-T-maze-task, a rodent model that
evaluates preference for vigorous physical activity vs. other more
sedentary sources of reinforcement (Correa et al., 2016; López-
Cruz et al., 2018; Carratalá-Ros et al., 2020). In the standard
version of this paradigm, no stressor is used, and mice have
been extensively in contact with the T-maze and the reinforcers
(2 weeks of BL). They can freely distribute their time performing
an effortful and highly preferred activity (running in a RW)
or engaging in more sedentary activities (eating sucrose pellets
or sniffing a fruit odor). Under basal conditions, mice spent
most of their time running in the RW, some of the time eating
sucrose pellets or drinking a sucrose solution in other versions
of the T-maze, and very little time sniffing the neutral odor
(Correa et al., 2016, 2020). In this experiment, the highest
dose of fluoxetine (20.0 mg/kg) significantly decreased the
time mice spent running and partially shifted their behavior,
increasing time consuming sucrose pellets in comparison with
the vehicle condition (Figure 4). This increase in time consuming
sucrose is also seen in terms of the amount of food consumed;
the highest dose of fluoxetine significantly increased intake of
sucrose in milligrams (around 170%, Table 1). This pattern of
effects is surprisingly similar to the pattern previously observed
for TBZ alone in this paradigm (López-Cruz et al., 2018;
Carratalá-Ros et al., 2020). The administration of different
doses of TBZ produced a partial shift; mice spent less time
running and increased time spent consuming sucrose pellets
in comparison with the vehicle condition. TBZ alone also
tended to increase total milligrams consumed, but the increase
was milder (around 35–50%), and never reached significance
(Carratalá-Ros et al., 2020). The present fluoxetine-induced
increase in food consumption has not been observed in rats
in operant choice procedures, and in fact, fluoxetine decreased
lever pressing for palatable food as well as intake of chow
(Yohn et al., 2016b). It is possible that this discrepancy is
due to differences between these two species. Male rats tend
to consume proportionally more food and are less active than
mice in T-maze paradigms (Presby et al., 2020). Thus, it is
possible that mice are more sensitive to the anergic effects of
fluoxetine (Table 2), and much less to its appetite suppressant
effects. Moreover, although previous clinical studies have shown
how this SERT blocker decreases appetite (Silverstone, 1992;
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Michelson et al., 1999), a recent metanalysis study (Serralde-
Zúñiga et al., 2019) comparing different categories of anti-obesity
drugs indicates that, unlike other drugs, fluoxetine treatment
does not conclusively decrease weight, but there is a clear
increase in the risk for drowsiness and fatigue. In addition,
unlike TBZ alone, mice treated with 20.0 mg/kg of fluoxetine
showed avoidance for the RW in general; not only they spent
significantly less time running, in addition, they also reduced
the total number of entries into the RW compartment, an
effect that was not observed for the other compartments. This
is a pattern of effects that is similar to that produced by
introducing aversive conditions in the T-maze (Carratalá-Ros
et al., 2020). Placing an intense light over the RW, which is
known to induce anxiogenic effects in the DL, shifts behavior
from RW to food consumption, but animals also show place
avoidance for the RW compared to BL (Carratalá-Ros et al.,
2020). Thus, although fluoxetine may have anxiolytic effects in
other contexts, it is possible that in the context of the RW T-
maze, fluoxetine at this dose (Figure 2) is having anxiogenic
effects, or producing an aversion to the RW. However, those
results are different from the pattern observed for TBZ, which
did not change any of these parameters; mice still highly
preferred to spend time in the compartment with the active
reinforcer (the RW compartment) after TBZ administration,
although they did not run as much (Carratalá-Ros et al.,
2020).
In the next experiment, different doses of fluoxetine were
unable to reverse the partial shift from RW towards food induced
by TBZ (Figure 5). However, fluoxetine at all doses suppressed
the TBZ-induced increase in time consuming sucrose, making
the combined administration of the two drugs no different
from control conditions. In previous studies in rats, fluoxetine
consistently failed to reverse the lever pressing suppression
induced by TBZ (Yohn et al., 2016b). But when animals were
tested on fluoxetine alone, they did not shift their behavior
from high effort/highly palatable food to free chow available
in the operant chamber, as is typical for TBZ (Yohn et al.,
2016c). In fact, in these experiments, fluoxetine also reduced
chow consumption (Yohn et al., 2016c). Thus, it seems that
fluoxetine in combination with TBZ produces both; anergic
effects and appetite suppressant effects in rats and mice. For
that reason, we wanted to evaluate the effects of conditions
related to appetite and food reinforcement on the T-maze choice
task, to compare those actions with the effects of fluoxetine
plus TBZ (Figures 6, 7). We devalued sucrose reinforcement
by pre-feeding the mice with the same type of sucrose pellets
the night before the test, or by adding quinine to the sucrose
pellets in order to make them bitter. Both manipulations
produced a significant shift in behavior substantially different
from those produced by fluoxetine or TBZ; devaluation of
sucrose reinforcement reduced almost to zero the time mice
spent consuming sucrose pellets in comparison with the BL
condition, but significantly increased time running, which was
not observed in the pharmacological interaction experiment
(Figure 5). Moreover, pre-feeding or making the pellets bitter led
to a robust and significant reduction of milligrams consumed,
which did not occur either with TBZ alone, and did not reach
significance with TBZ plus fluoxetine (Table 1). Previous results
have shown that the effects of DA antagonists and TBZ do
not resemble the effects of reinforcer devaluation on effort-
based choice performance in rats (Randall et al., 2012, 2014)
and mice (Yang et al., 2020). Thus, the present results strongly
confirm that the actions of TBZ on these paradigms should not
be interpreted as an effect on the primary or unconditioned
reinforcing value of food, or a food ‘‘reward’’ effect, but rather
on the tendency to engage in activities that require exertion of
physical effort.
The disruptive effects on time running produced by
fluoxetine or fluoxetine in combination with TBZ in the
T-maze could be explained by general effects on locomotor
activity. Thus, in the anxiety paradigms, fluoxetine (15.0 and
20.0 mg/kg), or fluoxetine (20.0 mg/kg) plus TBZ reduced
locomotion, as measured by the total number of entries into
compartments and crosses between arms (Figures 2B, 3B,E).
Moreover, in all the experiments, the number of overall crosses
between compartments in the T-maze was only significantly
reduced after fluoxetine (20.0 mg/kg) or fluoxetine plus TBZ
(Table 2 and Figure 5D). Previous studies have reported
that SERT blockade or deletion in mice reduced locomotion
(Holmes et al., 2002; Sanders et al., 2007), and fluoxetine
in rats that had received TBZ showed further decreased
locomotor activity compared with administration of TBZ alone
(Podurgiel et al., 2015).
The inability of fluoxetine to alleviate motivational
impairments induced by a DA depleting agent, and to induce
psychomotor deficits, could be due to the actions of fluoxetine
on the mesolimbic DA system (Cameron and Williams,
1995; Daw et al., 2002). Nacb core is a central nucleus for
the regulation of effort base-decision making (Cameron and
Williams, 1995; Daw et al., 2002). Fluoxetine alone decreased
DA levels in Nacb core as measure by microdyalisis (Yohn et al.,
2016c), and co-administration of TBZ and fluoxetine further
decreased DA tissue levels in the rat ventrolateral neostriatum
compared with TBZ alone (Podurgiel et al., 2015). Nacb
receives projections from dorsal raphe nuclei 5-HT neurons,
and the stimulation of these neurons decreases DA mesolimbic
activity (Ichikawa and Meltzer, 1995; di Mascio et al., 1998;
di Giovanni et al., 2000; di Matteo et al., 2008; Browne et al.,
2019). Thus, the combination of fluoxetine with TBZ, which
also has been demonstrated to reduce DA tissue content and
release (Nunes et al., 2013; Podurgiel et al., 2015; López-Cruz
et al., 2018), suggests that these impairments in behavioral
activation assessed in the 3-choice-T-maze task and in the FST
could be produced by an overall reduction of mesolimbic DA
activity.
In summary, acute fluoxetine energized behavior under
stressful conditions in the FST but did not reverse the anergic
effects produced by TBZ in either the FST or the 3-choice-T-
maze task. Although acute and chronic fluoxetine had the same
impairing effects in an effort-choice test in rats (Yohn et al.,
2016b,c,e), because fluoxetine is administered chronically as an
antidepressant, further studies should evaluate if this pattern of
administration of fluoxetine can improve the impairing effects of
TBZ in the 3-choice-T-maze task.
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Although several clinical reports suggest that fluoxetine is
relatively ineffective for treating psychomotor and motivational
symptoms seen in depression and, in fact, it can exacerbate or
induce these effects (Katz et al., 2004; Nutt et al., 2007; Padala
et al., 2012; Rothschild et al., 2014), it should be pointed out that
drugs that facilitate 5-HT can treat other aspects of depression
such as mood dysfunction, rumination, and cognitive arousal
(Carr and Lucki, 2011; Bell et al., 2013) and, as seen in the present
study as well as previous studies, fluoxetine administered alone
produces an effective response in classical antidepressant tests
such as the FST (Armario et al., 1988; Cryan et al., 2005a,b; Jang
et al., 2009).
Thus, the present studies are consistent with the idea
that not all antidepressants are adequate for the treatment of
psychomotor slowing and anergia symptoms commonly seen
in depression. This idea of different therapeutic drugs having
positive actions for some symptoms, but no effect or even
negative actions on other symptoms, is consistent with the
research domain criterion (RDoC) approach that highlights the
importance of describing the neural circuits that mediate specific
symptoms in psychopathology, and not simply the traditional
diagnostic categories (Cuthbert and Insel, 2013).
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